PT-141 (Bremelanotide)
Research Material
- AreaSexual Health
- CAS189691-06-3
- Purity≥99%
$39.95
View Material →
PT-141 Liquid Spray supplies Bremelanotide, a synthetic cyclic heptapeptide melanocortin receptor agonist, in a pre-dissolved liquid intranasal spray format rather than a lyophilized vial. The active compound is chemically identical to vial-form PT-141 (formula C₅₀H₆₈N₁₄O₁₀, molecular weight approximately 1,025.17 g/mol, CAS 189691-06-3, PubChem CID 9941379), built on an N-terminal acetylated norleucine residue and a cyclic lactam bridge with a D-phenylalanine substitution that constrains the scaffold and improves metabolic stability. The liquid format is provided to support research workflows that require a solution-phase or intranasal delivery configuration.
As with the vial, PT-141 is studied as a nonselective agonist across the MC1R, MC3R, MC4R, and MC5R melanocortin receptor subtypes, with particular research attention on MC4R signaling in central neuroendocrine models. This spray is supplied as a reference material for laboratory and in vitro research use only and is not intended for human or veterinary use.
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Bremelanotide is characterized in the literature as a high-affinity, nonselective melanocortin receptor agonist with predominant functional activity at MC1R and MC4R. Reported animal-model findings link MC4R activation in the medial preoptic area of the hypothalamus to downstream dopamine release. Delivered in a solution-phase spray format, the compound retains the same molecular identity as the lyophilized vial; researchers typically confirm concentration and stability of pre-dissolved peptide solutions as part of experimental characterization.
PT-141 (Bremelanotide) was developed as a cyclic heptapeptide analog derived from the linear melanocortin agonist Melanotan II and became one of the most extensively studied melanocortin receptor agonists. Under the name Bremelanotide (Vyleesi), it received FDA approval in June 2019 for a specific human clinical indication. Liquid and intranasal spray formats have historically been used in research settings as alternatives to reconstituted lyophilized powder.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. PT-141 Liquid Spray is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.